Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CVAC CureVac	$5.44 +1.5%	$4.15	$2.37 ▼ $5.72	$1.20B	2.49	811,517 shs	1.11 million shs
GPCR Structure Therapeutics	$21.79 -2.6%	$23.46	$13.22 ▼ $47.48	$1.28B	-1.87	846,714 shs	704,601 shs
IVA Inventiva	$3.07 -1.9%	$3.44	$1.53 ▼ $4.05	$299.42M	0.75	64,463 shs	30,714 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+3.01%
CVAC CureVac	+1.49%	-0.91%	+33.01%	+94.29%	+53.67%
GPCR Structure Therapeutics	-2.64%	+0.79%	-11.24%	+9.28%	-45.47%
IVA Inventiva	-1.92%	-7.84%	-1.76%	+4.42%	+0.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	4.5509 of 5 stars	4.2	4.0	0.0	4.8	1.9	0.0	1.3
GPCR Structure Therapeutics	2.314 of 5 stars	3.5	2.0	0.0	0.0	1.9	1.7	0.6
IVA Inventiva	1.8339 of 5 stars	3.4	2.0	0.0	0.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CVAC CureVac	2.40	Hold	$9.00	65.44% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	249.55% Upside
IVA Inventiva	2.80	Moderate Buy	$10.40	238.76% Upside

Current Analyst Ratings Breakdown

Latest IVA, GPCR, CVAC, and CALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00
6/12/2025	CVAC CureVac	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
6/12/2025	CVAC CureVac	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/28/2025	CVAC CureVac	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$10.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/30/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/4/2025	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $9.00

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CVAC CureVac	$579.18M	2.11	$0.89 per share	6.14	$3.36 per share	1.62
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
IVA Inventiva	$9.95M	29.52	N/A	N/A	($1.21) per share	-2.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CVAC CureVac	$175.50M	$0.92	5.91	N/A	N/A	35.44%	30.89%	25.54%	8/13/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest IVA, GPCR, CVAC, and CALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
4/10/2025	Q4 2024	CVAC CureVac	-$0.14	-$0.15	-$0.01	-$0.15	$6.40 million	$15.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CVAC CureVac	0.05	7.65	7.64
GPCR Structure Therapeutics	N/A	23.29	23.29
IVA Inventiva	N/A	0.92	0.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
CVAC CureVac	17.26%
GPCR Structure Therapeutics	91.78%
IVA Inventiva	19.06%

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
CVAC CureVac	2.15%
GPCR Structure Therapeutics	9.43%
IVA Inventiva	32.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
CVAC CureVac	880	224.34 million	219.52 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable

IVA, GPCR, CVAC, and CALT Headlines

Recent News About These Companies

Inventiva S.A. (IVA) Latest Stock News & Headlines - Yahoo Finance

June 24 at 10:27 PM | finance.yahoo.com

Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target

June 24 at 5:26 PM | msn.com

Inventiva appoints former Calliditas CEO to board of directors

June 11, 2025 | uk.investing.com

Inventiva (NASDAQ:IVA) Stock Price Up 0.8% - Here's Why

June 11, 2025 | marketbeat.com

INVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

June 11, 2025 | finanznachrichten.de

Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

June 10, 2025 | manilatimes.netM

Inventiva S.A. (NASDAQ:IVA) Short Interest Down 12.1% in May

June 4, 2025 | marketbeat.com

Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?

June 3, 2025 | zacks.com

INVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 27, 2025 | finanznachrichten.de

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 27, 2025 | globenewswire.com

Inventiva S.A. reports Q1 results

May 23, 2025 | seekingalpha.com

INVENTIVA: Inventiva reports 2025 First Quarter Financial Information

May 23, 2025 | finanznachrichten.de

Inventiva reports 2025 First Quarter Financial Information¹

May 23, 2025 | globenewswire.com

Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

May 23, 2025 | globenewswire.com

Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux

May 22, 2025 | uk.finance.yahoo.com

INVENTIVA: Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

May 6, 2025 | finanznachrichten.de

Inventiva Secures €115.6 Million Through T2 Subscription Agreement

May 5, 2025 | tipranks.com

Inventiva secures €116 million second tranche of structured financing of up to €348 million

May 5, 2025 | msn.com

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

May 5, 2025 | globenewswire.com

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

April 30, 2025 | globenewswire.com

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

April 24, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Why SailPoint May Cruise Past Cybersecurity Rivals in 2025
By Nathan Reiff | June 18, 2025
View Why SailPoint May Cruise Past Cybersecurity Rivals in 2025

IVA, GPCR, CVAC, and CALT Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 06/24/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

CureVac NASDAQ:CVAC

$5.44 +0.08 (+1.49%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$5.45 +0.01 (+0.18%)

As of 06/25/2025 07:52 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Structure Therapeutics NASDAQ:GPCR

$21.79 -0.59 (-2.64%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$21.84 +0.05 (+0.21%)

As of 06/25/2025 07:58 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Inventiva NASDAQ:IVA

$3.07 -0.06 (-1.92%)

As of 06/25/2025 04:00 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time